Lataa...
The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of hematological and non-hematological malignancies. However, its antitumor activity has not been tested in human breast cancer. This study aimed to investigate the effect of...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4365748/ https://ncbi.nlm.nih.gov/pubmed/25834401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S75378 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|